Analysts Forecast Forte Biosciences' FY2030 Earnings

Brookline Capital Markets issues projections for the biotech company's future performance

Apr. 8, 2026 at 12:37pm

Got story updates? Submit your updates here. ›

Forte Biosciences, Inc. (NASDAQ:FBRX) - Investment analysts at Brookline Capital Markets have released their FY2030 earnings per share (EPS) estimates for the biotech company. Brookline Capital Markets analyst K. Raja expects Forte Biosciences to earn ($6.07) per share in the year 2030, compared to the current full-year consensus estimate of ($12.12) per share.

Why it matters

Forte Biosciences is a clinical-stage biotech company focused on developing treatments for dermatological conditions. Analyst projections for the company's long-term financial performance provide insights into the market's expectations and potential growth trajectory for the business.

The details

In a research note issued to investors on Monday, April 6th, Brookline Capital Markets analyst K. Raja outlined their FY2030 EPS forecast for Forte Biosciences. The analyst expects the company to earn ($6.07) per share in the year 2030, compared to the current full-year consensus estimate of ($12.12) per share. This suggests analysts see potential for Forte Biosciences to improve its financial performance over the next decade.

  • Brookline Capital Markets issued their FY2030 EPS estimates on Monday, April 6th.
  • Forte Biosciences last reported quarterly earnings on Tuesday, March 31st.

The players

Forte Biosciences, Inc.

A clinical-stage biotechnology company focused on developing innovative treatments to restore skin health by targeting the underlying biology of the skin barrier and microbiome.

Brookline Capital Markets

An investment research firm that issued FY2030 earnings projections for Forte Biosciences.

K. Raja

An analyst at Brookline Capital Markets who provided the FY2030 EPS estimate for Forte Biosciences.

Got photos? Submit your photos here. ›

What they’re saying

“Brookline Capital Markets analyst K. Raja expects that the company will earn ($6.07) per share for the year.”

— K. Raja, Analyst

The takeaway

Analyst projections for Forte Biosciences' long-term financial performance suggest the market sees potential for the company to improve its earnings outlook over the next decade, though the current consensus estimate remains negative. This could signal optimism about the company's clinical pipeline and ability to commercialize successful dermatological treatments.